Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of ARD-101 in Subjects At Least One Year After Bariatric Surgery

NCT05215847 is registered in ClinicalTrials.gov with Aardvark Therapeutics, Inc. as lead sponsor.

NCT NCT05215847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05215847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of ARD-101 in Subjects At Least One Year After Bariatric Surgery
Lead sponsor
Aardvark Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2022
Completion date
February 3, 2023
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bariatric surgery, obesity, weight gain